Hospitals

Servier India introduces ‘Ivosidenib’(Tibsovo®), in India, First-in-class Targeted Therapy in Oncology

admin
Chennai, June 2025 Servier India, a subsidiary of the leading French pharmaceutical Servier Group, announced the launch ofIvosidenib (Tibsovo®), an oral targeted therapy approved in the management of cancer patients with Acute Myeloid Leukemia (AML) and Cholangiocarcinoma, with an isocitrate dehydrogenase-1 (IDH1) mutation. Servier...